Serial Retinal Thickness Changes and Scotoma Size Measured with Lucentis Therapy measured Using the OCT Ophthalmoscope (OCT/SLO)® and the Foresee Preferential Hyperacuity Perimeter TM PROTOCOL FVF4193s

Principal Investigator

Richard Rosen, MD

Enrollment Status

Open Enrollment

Objective

To evaluate the efficacy of intravitreal bevasiranib sodium as maintenance therapy for Age-Related Macular Degeneration following initiation of anti-VEGF therapy with 3 doses of Lucentis®

Contact Information 

Melissa Rivas, CRC 
(212)-614-8386

Katy Tai, CR Manager
(212) 979-4251

 

Home > Current Research > Clinical Trials in Ophthalmology > SERIAL RETINAL THICKNESS CHANGES AND SCOTOMA SIZE MEASURED WITH LUCENTIS THERAPY MEASURED USING THE OCT OPHTHALMOSCOPE (OCT/SLO)® AND THE FORESEE PREFERENTIAL HYPERACUITY PERIMETER TM PROTOCOL FVF4193S